Crescent Biopharma (CBIO) Depreciation and Depletion (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Depreciation and Depletion of $66000.0 for Q2 2026, up 3200.0% year-over-year from $2000.0 in Q2 2025, and up 3.12% quarter-over-quarter from $64000.0 in Q1 2026.
Crescent Biopharma (CBIO) Depreciation and Depletion (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Depreciation and Depletion for 14 consecutive years, with $66000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation and Depletion rose 3200.0% year-over-year to $66000.0; the TTM figure through Jun 2026 stood at $212000.0 (up 10500.0% YoY), while the FY2025 annual figure was $84000.0, up 138.81% from the prior year.
- Depreciation and Depletion advanced to $66000.0 in Q2 2026 per CBIO's latest filing, from $64000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $66000.0 in Q2 2026 and bottomed at $2000.0 in Q2 2025.
- Historically, Depreciation and Depletion has averaged $40099.4 across 5 years, with a median of $43839.0 in 2023.
- Annual changes were most pronounced in 2025 — Depreciation and Depletion plunged 83.9% — and 2026, when it surged 3200.0%.
- Crescent Biopharma's Depreciation and Depletion stood at $45718.0 in 2022, then tumbled by 49.04% to $23297.0 in 2023, then slumped by 46.68% to $12423.0 in 2024, then jumped by 334.68% to $54000.0 in 2025, then climbed by 22.22% to $66000.0 in 2026.
- Business Quant data shows CBIO's Depreciation and Depletion at $66000.0 in Q2 2026, $64000.0 in Q1 2026, and $54000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66,000.00 |
| Jun 30, 2026 | 66,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2024 | 12,423.00 |
| Jun 30, 2024 | 12,423.00 |
| Mar 31, 2024 | 14,620.00 |
| Mar 31, 2024 | 14,620.00 |
| Dec 31, 2023 | 23,297.00 |
| Dec 31, 2023 | 23,297.00 |
| Sep 30, 2023 | 42,747.00 |
| Sep 30, 2023 | 42,747.00 |
| Jun 30, 2023 | 43,419.00 |
| Jun 30, 2023 | 43,419.00 |